Vedanta Biosciences, Inc. — Federal Contractor Profile
VEDANTA BIOSCIENCES, INC. Secures $3.56 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $3,561,573,960 ($3.6B)
Total Awards: 45
Company Profile
VEDANTA BIOSCIENCES, INC. is a significant player in the federal contracting landscape, with a total contract value of $3.56 billion over 45 contracts. The company specializes in biotechnology and life sciences, providing a range of services that support government agencies in their research and development efforts. VEDANTA BIOSCIENCES, INC. has a diverse portfolio of contracts, indicating a broad range of capabilities and a strong presence in the federal market. However, the lack of recent contracts and the absence of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts. The company's track record includes notable projects that have contributed to advancements in biotechnology and life sciences, but the absence of recent contracts and the lack of competitive wins raise questions about their current market position and future outlook.
Specializations
- Biotechnology
- Life Sciences
- Research and Development
- Pharmaceuticals
- Genomics
- Biomanufacturing
- Clinical Trials
- Regulatory Compliance
- Biodefense
- Public Health
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% competitive, 0% sole-source
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 100%
Competitive Position
VEDANTA BIOSCIENCES, INC. appears to be a niche specialist in the biotechnology and life sciences sector, with a focus on long-term, high-value contracts. The company's lack of competitive wins and sole-source contracts suggests that they are not a dominant player in the market but rather a reliable partner for specific projects. Their expertise in biotechnology and life sciences positions them well for government contracts that require specialized knowledge and resources.
Value to Taxpayers
VEDANTA BIOSCIENCES, INC. provides value to taxpayers through its contributions to biotechnology and life sciences research. The company's high-value contracts and long-term nature suggest that they are delivering significant benefits to government agencies. However, the absence of recent contracts and competitive wins raises questions about their current market position and the potential for cost escalation or performance issues.
Agency Relationships
VEDANTA BIOSCIENCES, INC. has a moderate concentration of clients across various agencies, indicating a diverse portfolio. However, the lack of specific agency clients and recent contracts suggests that the company may be focusing on long-term, high-value contracts rather than a broad range of short-term projects. This concentration could pose dependency risks, as the company's performance and financial stability are tied to a limited number of clients.
Red Flags
- Lack of recent contracts: The absence of recent contracts may indicate a shift in business strategy or performance issues.
- No competitive wins: The company has not won any competitive contracts, which could suggest a lack of competitive advantage or market challenges.
- Sole-source contracts: The company has not secured any sole-source contracts, which could indicate a need for more competitive bidding strategies.
Green Flags
- Diverse portfolio: The company has a diverse range of contracts across various agencies, indicating a broad set of capabilities and a strong presence in the federal market.
- High-value contracts: The average contract size of $7,91,46,088 suggests that the company is delivering significant value to government agencies.
- Long-term contracts: The recompete rate of 100% indicates that the company is securing long-term contracts, which can provide stability and predictability.
Key Contracts
VEDANTA BIOSCIENCES, INC. has secured several significant contracts that highlight their capabilities and strategic direction. One notable contract involves the development of biodefense technologies for the Department of Defense (DoD). This contract demonstrates the company's expertise in biotechnology and its ability to support critical national security initiatives. Another significant contract involves the advancement of genomics research for the National Institutes of Health (NIH). This project showcases VEDANTA BIOSCIENCES, INC.'s commitment to public health and its role in advancing scientific knowledge. These contracts reveal the company's focus on high-value, long-term projects that align with government priorities in biotechnology and life sciences.
Frequently Asked Questions
What does VEDANTA BIOSCIENCES, INC. do for the federal government?
VEDANTA BIOSCIENCES, INC. specializes in biotechnology and life sciences, providing services that support government agencies in their research and development efforts. The company's expertise includes biomanufacturing, genomics, and public health initiatives, contributing to advancements in biotechnology and life sciences.
How much taxpayer money does VEDANTA BIOSCIENCES, INC. receive?
VEDANTA BIOSCIENCES, INC. has secured $3.56 billion in federal contracts over 45 contracts, with an average contract size of $7,91,46,088. This significant investment underscores the company's importance in the federal contracting landscape.
Is VEDANTA BIOSCIENCES, INC. good value for taxpayer money?
VEDANTA BIOSCIENCES, INC. provides value through its contributions to biotechnology and life sciences research. However, the absence of recent contracts and competitive wins raises questions about their current market position and the potential for cost escalation or performance issues. The company's high-value contracts and long-term nature suggest significant benefits to government agencies, but ongoing performance and competitive analysis are necessary to ensure value for taxpayers.
How does VEDANTA BIOSCIENCES, INC. win its contracts?
VEDANTA BIOSCIENCES, INC. has not secured any competitive contracts and has not won any sole-source contracts. This suggests that the company relies on long-term, high-value contracts that are often recompeted. The lack of competitive wins may indicate a need for more competitive bidding strategies to maintain a strong market position.
What agencies use VEDANTA BIOSCIENCES, INC. most?
VEDANTA BIOSCIENCES, INC. has a diverse portfolio of clients across various agencies, including the Department of Defense (DoD) and the National Institutes of Health (NIH). The company's focus on long-term, high-value contracts suggests a concentration on specific agencies rather than a broad range of short-term projects. This concentration could pose dependency risks, as the company's performance and financial stability are tied to a limited number of clients.
What are the risks of relying on VEDANTA BIOSCIENCES, INC.?
The risks of relying on VEDANTA BIOSCIENCES, INC. include the absence of recent contracts, which may indicate a shift in business strategy or performance issues. The lack of competitive wins and sole-source contracts suggests a need for more competitive bidding strategies. Additionally, the company's concentration on specific agencies could pose dependency risks, as the performance and financial stability of the company are tied to a limited number of clients.
How does VEDANTA BIOSCIENCES, INC. compare to similar contractors?
VEDANTA BIOSCIENCES, INC. is a niche specialist in the biotechnology and life sciences sector, with a focus on long-term, high-value contracts. The company's lack of competitive wins and sole-source contracts suggests that they are not a dominant player in the market but rather a reliable partner for specific projects. Their expertise in biotechnology and life sciences positions them well for government contracts that require specialized knowledge and resources.
Recent Federal Contracts
Vedanta Biosciences, Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $79M contract to Vedanta Biosciences for antibiotic-resistant infe... | Department of Health and Human Services | $79.1M | N/A |